相关实验视频
Updated: Jan 13, 2026

04:27
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
6.0K
在早产婴儿中,皮松的使用与儿童心血管不良结果无关
Cherine Benzouid1, Plamen Bokov2, Pierre Coste3
1Department of Physiology, AP-HP, Robert Debré Hospital, Paris, France.
Pediatric research
|January 9, 2026
概括
在极度早产的婴儿中,早期的皮松给药与儿童期的不良心血管结果无关. 然而,超重和肥胖与该人口中心血管风险因素的增加有关.
科学领域:
- 新生儿医学 新生儿医学
- 儿科心脏病学 儿科心脏病学
- 临床试验中的临床试验.
背景情况:
- 评估在极度早产婴儿中经产期间给药的皮的长期心血管影响.
- 调查早期皮质类固醇暴露与晚期心血管健康之间的潜在联系.
研究的目的:
- 为了确定在产周期间给予的皮松是否与儿童和青少年的不良心血管结果有关.
- 为了评估在PREMILOC试验中接受皮和安慰剂的儿童的心血管参数.
主要方法:
- 利用静止血压 (BP) 测量,度 (脉冲波速度,大动脉缩BP),连续BP和心电图监测,以及门诊BP监测.
- 参与者的心率变化 (HRV) 指数,巴罗反射灵敏度 (BRS) 和静态静脉血压 (SBP) 响应的计算.
- 招募了52名受试者 (平均出生体重892g,妊娠年龄26周),评估时的平均年龄为11.7岁.
主要成果:
- 在皮和安慰剂组之间没有发现脉冲波速度 (PWV),HRV或BP测量的显著差异.
- 超重/肥胖儿童 (n=17) 与其他儿童 (n=35) 相比,表现出更高的办公室SBP,更低的卧底下降BRS,以及更高的静态SBP反应.
结论:
- 在极度早产的婴儿中,早期给予皮并没有与儿童时期有害的心血管指数有关.
- 在这个队列中,超重/肥胖被确定为与心血管疾病相关的重要因素.
- 这项研究表明,高血压风险的早期标志物不会因周产期皮暴露而改变.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
COPD: Management Using Bronchodilators and Corticosteroids
719
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
719
Drug Dosing: Infants and Children
248
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
248
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K

